Achieve Life Sciences - Receives Grant for Cessation of Nicotine E-cigarette Use

Health Professional Radio - Podcast

Dr. Cindy Jacobs, PhD, MD, President and Chief Medical Officer at Achieve Life Sciences discusses the grant that was awarded from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for the cessation of nicotine e-cigarette use.

#AchieveLifeSciences

Cindy Jacobs, Ph.D., M.D. · President & Chief Medical Officer, Achieve Life Sciences Inc. Dr. Jacobs is an experienced executive in drug development with expertise in several indications and over 30 years’ experience in Biotechnology/Pharmaceutical industry. Dr Jacobs has achieved regulatory success in several product approvals. Prior to joining Achieve Life Sciences in 2017, Dr. Jacobs served as OncoGenex’s Executive Vice President and Chief Medical Officer since August 2008, and had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Bachelor’s degree in Microbiology from Montana State University, her Master’s degree and Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. She has in-depth biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, clinical operations, Phase 1-4 trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. Based on her preclinical work at Immunex Corporation, she is one of 2 inventors on the patent for Enbrel.